Staying current with the literature was impossible. Until now.
Lorundrostat at 50 mg/d and 100 mg/d reduced systolic blood pressure by -16.9 mm Hg at week 6 versus -7.9 mm Hg for placebo in patients with uncontrolled and treatment-resistant hypertension.
An international, double-blind, randomized, placebo-controlled trial evaluating evolocumab in patients with atherosclerosis or diabetes who had not experienced a previous myocardial infarction or stroke.
The US POINTER trial compared structured versus self-guided multidomain lifestyle interventions including exercise, diet, cognitive stimulation, and vascular risk management for preventing cognitive decline in older adults.
Obesity increases the risk of type 2 diabetes, hypertension, chronic kidney disease, and cardiovascular disease. Cardiovascular outcome trials of incretin-based medicines tirzepatide and semaglutide have shown benefits across varying levels of cardiovascular risk.
Current clinical practice recommendations from the American Diabetes Association providing updated evidence-based guidelines for cardiovascular disease prevention and management in patients with diabetes.
A longitudinal study examining the relationship between gut microbiome composition changes, uremic toxin accumulation, and diet on CKD severity. A plant-based low protein diet appeared to mitigate changes in uremic toxin-producing species over time.
A phase 2b randomized, double-blind, placebo-controlled trial evaluating once-weekly navepegritide in children with achondroplasia, conducted at 10 hospitals across Australia, Canada, Denmark, Ireland, and New Zealand.
Four-year findings from the VITAL trial examining the effects of vitamin D3 (2,000 IU/day) and marine omega-3 fatty acid supplementation on leukocyte telomere length in 25,871 US adults aged 50 and older.
Real-world cohort studies assessing the effectiveness of tirzepatide versus semaglutide on HbA1c and weight outcomes in patients with type 2 diabetes and elevated cardiovascular risk enrolled in US insurance programs.
A parallel randomized controlled trial targeting elderly patients over 60 years of age with heart failure, comparing an age-friendly intervention group (n=74) with a conventional treatment group (n=74) for self-management outcomes.
Lorundrostat at 50 mg/d and 100 mg/d reduced systolic blood pressure by -16.9 mm Hg at week 6 versus -7.9 mm Hg for placebo in patients with uncontrolled and treatment-resistant hypertension.
An international, double-blind, randomized, placebo-controlled trial evaluating evolocumab in patients with atherosclerosis or diabetes who had not experienced a previous myocardial infarction or stroke.
The US POINTER trial compared structured versus self-guided multidomain lifestyle interventions including exercise, diet, cognitive stimulation, and vascular risk management for preventing cognitive decline in older adults.
Obesity increases the risk of type 2 diabetes, hypertension, chronic kidney disease, and cardiovascular disease. Cardiovascular outcome trials of incretin-based medicines tirzepatide and semaglutide have shown benefits across varying levels of cardiovascular risk.
Current clinical practice recommendations from the American Diabetes Association providing updated evidence-based guidelines for cardiovascular disease prevention and management in patients with diabetes.
A longitudinal study examining the relationship between gut microbiome composition changes, uremic toxin accumulation, and diet on CKD severity. A plant-based low protein diet appeared to mitigate changes in uremic toxin-producing species over time.
A phase 2b randomized, double-blind, placebo-controlled trial evaluating once-weekly navepegritide in children with achondroplasia, conducted at 10 hospitals across Australia, Canada, Denmark, Ireland, and New Zealand.
Four-year findings from the VITAL trial examining the effects of vitamin D3 (2,000 IU/day) and marine omega-3 fatty acid supplementation on leukocyte telomere length in 25,871 US adults aged 50 and older.
Real-world cohort studies assessing the effectiveness of tirzepatide versus semaglutide on HbA1c and weight outcomes in patients with type 2 diabetes and elevated cardiovascular risk enrolled in US insurance programs.
A parallel randomized controlled trial targeting elderly patients over 60 years of age with heart failure, comparing an age-friendly intervention group (n=74) with a conventional treatment group (n=74) for self-management outcomes.
Examining nutritional interventions including fiber, phytochemicals, fermented foods, and traditional medicines, as well as probiotics and prebiotics for modulating the gut microbiota in pediatric CKD patients.
A double-blinded, randomized interventional non-inferiority trial evaluating the outcome of treating complex cryptoglandular perianal fistulas using minimal surgical debridement combined with adipose-derived regenerative cells.
Validation of the UKPDS outcomes model for estimating the risk of cardiovascular outcomes and all-cause mortality in individuals with type 2 diabetes using data from the TECOS and EXSCEL clinical trials.
From the DO-HEALTH trial, examining how vitamin D supplementation, omega-3 fatty acids, and a simple strength exercise programme individually and additively affect epigenetic clocks of biological aging in older adults.
Semaglutide and tirzepatide represent highly effective treatment options for people with type 2 diabetes and obesity, enabling control of glucose and weight loss while reducing cardiovascular and renal morbidity and mortality.
Compared to other anti-obesity medications, GLP-1RA use was associated with lower risks of major adverse cardiovascular events, major adverse kidney events, and all-cause mortality in adults with obesity without diabetes.
Meta-analysis of 47 randomized controlled trials examining GLP-1 receptor agonists for weight loss in patients with obesity or overweight. GLP-1 RAs demonstrated significant reductions, with a mean weight reduction of -4.57 kg compared with placebo.
Systematic review and meta-analysis of lifestyle modification combined with GLP-1 receptor agonists on body weight and cardiometabolic biomarkers in individuals with overweight or obesity.
Real-world analysis of utilization patterns, clinical and comparative effectiveness, and adverse effects of newer GLP-1 receptor agonist-based weight-loss therapies across large clinical populations.
Systematic review of randomized controlled trials examining efficacy and safety of GLP-1 receptor agonists for weight loss among adults with overweight or obesity but without diabetes.
Examining nutritional interventions including fiber, phytochemicals, fermented foods, and traditional medicines, as well as probiotics and prebiotics for modulating the gut microbiota in pediatric CKD patients.
A double-blinded, randomized interventional non-inferiority trial evaluating the outcome of treating complex cryptoglandular perianal fistulas using minimal surgical debridement combined with adipose-derived regenerative cells.
Validation of the UKPDS outcomes model for estimating the risk of cardiovascular outcomes and all-cause mortality in individuals with type 2 diabetes using data from the TECOS and EXSCEL clinical trials.
From the DO-HEALTH trial, examining how vitamin D supplementation, omega-3 fatty acids, and a simple strength exercise programme individually and additively affect epigenetic clocks of biological aging in older adults.
Semaglutide and tirzepatide represent highly effective treatment options for people with type 2 diabetes and obesity, enabling control of glucose and weight loss while reducing cardiovascular and renal morbidity and mortality.
Compared to other anti-obesity medications, GLP-1RA use was associated with lower risks of major adverse cardiovascular events, major adverse kidney events, and all-cause mortality in adults with obesity without diabetes.
Meta-analysis of 47 randomized controlled trials examining GLP-1 receptor agonists for weight loss in patients with obesity or overweight. GLP-1 RAs demonstrated significant reductions, with a mean weight reduction of -4.57 kg compared with placebo.
Systematic review and meta-analysis of lifestyle modification combined with GLP-1 receptor agonists on body weight and cardiometabolic biomarkers in individuals with overweight or obesity.
Real-world analysis of utilization patterns, clinical and comparative effectiveness, and adverse effects of newer GLP-1 receptor agonist-based weight-loss therapies across large clinical populations.
Systematic review of randomized controlled trials examining efficacy and safety of GLP-1 receptor agonists for weight loss among adults with overweight or obesity but without diabetes.
The WHO guideline provides evidence-based recommendations on the clinical use of GLP-1 receptor agonists for adults with obesity, including considerations for implementation in low- and middle-income countries.
A four-strain probiotic enriched gut microbiota with potential to reduce systemic inflammation, shorten time-to-on following levodopa administration, and alleviate non-motor symptoms in Parkinson disease patients with constipation.
Review of cross-talk mechanisms along the gut-brain axis and their implications in neuropsychiatric disorders such as depression, anxiety, Alzheimer disease, and Parkinson disease in patients with inflammatory bowel disease.
Narrative review integrating current research on how gut microbial dysbiosis may influence the development and progression of Alzheimer and Parkinson disease, and how alterations in gut microbiota composition may drive neurodegeneration.
Review of how the gut microbiome changes with age and how these changes contribute to inflammaging, frailty, and age-related diseases. Dietary and probiotic interventions show promise for modulating these effects.
Comprehensive review of mechanistic links between gut microbiome composition and human diseases including metabolic, cardiovascular, neurological, and autoimmune conditions, with analysis of therapeutic interventions.
Cohort study evaluating whether immune checkpoint inhibitor therapy is associated with a higher incidence of hypertension among cancer patients, with implications for cardiovascular monitoring during cancer immunotherapy.
Investigation of 2-year incidence and relative rates of progressive kidney dysfunction in patients treated with oral molecularly targeted cancer medications, clarifying distinctions between true AKI and reversible creatinine elevations.
Individual patient data meta-analysis confirming that rheumatoid arthritis confers increased fracture risk largely independent of bone mineral density, supporting its retention as a risk factor in future FRAX iterations.
The WHO guideline provides evidence-based recommendations on the clinical use of GLP-1 receptor agonists for adults with obesity, including considerations for implementation in low- and middle-income countries.
A four-strain probiotic enriched gut microbiota with potential to reduce systemic inflammation, shorten time-to-on following levodopa administration, and alleviate non-motor symptoms in Parkinson disease patients with constipation.
Review of cross-talk mechanisms along the gut-brain axis and their implications in neuropsychiatric disorders such as depression, anxiety, Alzheimer disease, and Parkinson disease in patients with inflammatory bowel disease.
Narrative review integrating current research on how gut microbial dysbiosis may influence the development and progression of Alzheimer and Parkinson disease, and how alterations in gut microbiota composition may drive neurodegeneration.
Review of how the gut microbiome changes with age and how these changes contribute to inflammaging, frailty, and age-related diseases. Dietary and probiotic interventions show promise for modulating these effects.
Comprehensive review of mechanistic links between gut microbiome composition and human diseases including metabolic, cardiovascular, neurological, and autoimmune conditions, with analysis of therapeutic interventions.
Cohort study evaluating whether immune checkpoint inhibitor therapy is associated with a higher incidence of hypertension among cancer patients, with implications for cardiovascular monitoring during cancer immunotherapy.
Investigation of 2-year incidence and relative rates of progressive kidney dysfunction in patients treated with oral molecularly targeted cancer medications, clarifying distinctions between true AKI and reversible creatinine elevations.
Individual patient data meta-analysis confirming that rheumatoid arthritis confers increased fracture risk largely independent of bone mineral density, supporting its retention as a risk factor in future FRAX iterations.
OnlyScience was purpose-built for medical literature.
Be the doctor they recommend.
Try it out for yourself!
Drop in lab results, clinical notes, imaging reports, or handwritten notes. Any format.
Our AI reads every document, pulls out every clinically relevant data point and assigns it to the relevant organ or organs.
Inspect your patient’s organs individually, see their medication history on a timeline, track their data over time, and much more.
Values in mg/dL · Normal range: 70–100